BRAF and neoplasm: In addition to the BRAF mutation, poorly differentiated (PDTCs) and anaplastic thyroid cancers (ATCs) often have other genetic and/or non-genetic alterations that can lead to the activation of certain signaling pathways involved in cancer cell growth and tumor progression.